Assetmark, Inc Taysha Gene Therapies, Inc. Transaction History
Assetmark, Inc
- $47.4 Billion
- Q4 2025
A detailed history of Assetmark, Inc transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Assetmark, Inc holds 8 shares of TSHA stock, worth $33. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8Holding current value
$33% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding TSHA
# of Institutions
169Shares Held
250MCall Options Held
463KPut Options Held
246K-
Rtw Investments, LP New York, NY24.4MShares$103 Million1.03% of portfolio
-
Ra Capital Management, L.P. Boston, MA23.6MShares$99.2 Million1.27% of portfolio
-
Avoro Capital Advisors LLC New York, NY21.7MShares$91.4 Million0.93% of portfolio
-
Morgan Stanley New York, NY19.3MShares$81.3 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY13.4MShares$56.3 Million0.01% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $204M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...